New generation of bioactive coating for intravenous catheters and implantable medical devices to prevent infections and thrombosisbroad
Coati-X · Horizon Europe grant · 2024-04-01–2027-03-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-TRANSITION-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2023-TRANSITIONOPEN-01. CORDIS record →
Objective
Catheters and implantable medical devices contacting with the bloodstream are sources of internal blood infections and thrombosis. Catheter-related bloodstream infections are one of the major causes of patient morbidity and mortality in intensive care units. Both thrombosis and catheter-related infections are leading to prolonged hospital stay, increased risks of mortality and high costs for healthcare system. Currently there is no coating technology on the market that allows preventing these two complications at once. We developed a new innovative coating technology that enables simultaneous prevention of thrombosis and internal bloodstream infections. This coating is made of layer-by-layer cross-linked nanogels that can be loaded with an antithrombotic and/or antibiotic drug. We found that layer-by-layer assembly of these nanogels controls the amount of releasable bioactive agents from coated-surfaces. Innovation of our technology is linked to the wider space of used nanoreservoirs that can entrap several bioactive molecules thus combining several biological activities in a single coating. In addition, these nanoreservoirs can be deposited as a coating on the surface of any biomaterial or medical device, whether metallic, biological, or polymeric.We have built a consortium that combines the key technical and business experience to bring our innovative coating product to market readiness. CMD-Coat, a young SME, counts with top researchers and specialists in the field of cardiovascular diseases, biologists, chemists and pharmacist. Fresci is a company specializing on the business strategy and innovation management. Together we aim to accelerate the technological development and validation of our Coati-X technology and bring to the market a new bioactive coating solution for implantable medical devices.
Beneficiaries (2)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| CM4CURE SA | BE | coordinator | €2,074,350 | Yes |
| SCIENCE&STRATEGY SL | ES | participant | €401,994 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.